TESARO, Inc. (TSRO) Receives Buy Rating from Lake Street Capital
Lake Street Capital restated their buy rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note released on Thursday morning. Lake Street Capital currently has a $143.00 price objective on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on the company. HC Wainwright reissued a buy rating on shares of TESARO in a report on Wednesday. Morgan Stanley reissued an overweight rating and issued a $165.00 price target (down previously from $181.00) on shares of TESARO in a report on Wednesday. Zacks Investment Research raised TESARO from a sell rating to a hold rating in a report on Wednesday. Cann reissued a buy rating and issued a $199.00 price target on shares of TESARO in a report on Tuesday. Finally, Jefferies Group LLC reissued a hold rating and issued a $124.00 price target on shares of TESARO in a report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $161.72.
Shares of TESARO (TSRO) traded up $0.08 during midday trading on Thursday, hitting $91.09. The company had a trading volume of 1,062,200 shares, compared to its average volume of 1,028,935. TESARO has a 1-year low of $89.00 and a 1-year high of $192.94. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.41 and a current ratio of 4.73.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The business’s revenue was up 740.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.72) EPS. research analysts forecast that TESARO will post -8.21 earnings per share for the current year.
WARNING: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/11/tesaro-inc-tsro-receives-buy-rating-from-lake-street-capital.html.
In related news, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,692 shares of company stock worth $4,628,976. 40.50% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Exane Derivatives acquired a new position in shares of TESARO in the 3rd quarter worth $106,000. Botty Investors LLC acquired a new position in shares of TESARO in the 2nd quarter worth $140,000. Nordea Investment Management AB acquired a new position in shares of TESARO in the 2nd quarter worth $167,000. Oppenheimer Asset Management Inc. grew its holdings in shares of TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in shares of TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,130 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.